• Home
  • Search Results
  • Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients.

Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients.

British journal of clinical pharmacology (2014-07-22)
Antonio J López-Farré, Pablo Rodriguez-Sierra, Javier Modrego, Antonio Segura, Naiara Martín-Palacios, Ana M Saiz, José J Zamorano-León, Juan Duarte, Javier Serrano, Guillermo Moñux
ABSTRACT

Further to its pivotal role in haemostasis, factor Xa (FXa) promotes effects on the vascular wall. The purpose of the study was to evaluate if FXa modifies the expression level of energy metabolism and oxidative stress-related proteins in femoral arteries obtained from type 2 diabetic patients with end-stage vasculopathy. Femoral arteries were obtained from 12 type 2 diabetic patients who underwent leg amputation. Segments from the femoral arteries were incubated in vitro alone and in the presence of 25 nmol l(-1) FXa and 25 nmol l(-1) FXa + 50 nmol l(-1) rivaroxaban. In the femoral arteries, FXa increased triosephosphate isomerase and glyceraldehyde-3-phosphate dehydrogenase isotype 1 expression but decreased pyruvate dehydrogenase expression. These facts were accompanied by an increased content of acetyl-CoA. Aconitase activity was reduced in FXa-incubated femoral arteries as compared with control. Moreover, FXa increased the protein expression level of oxidative stress-related proteins which was accompanied by an increased malonyldialdehyde arterial content. The FXa inhibitor, rivaroxaban, failed to prevent the reduced expression of pyruvate dehydrogenase induced by FXa but reduced acetyl-CoA content and reverted the decreased aconitase activity observed with FXa alone. Rivaroxaban + FXa but not FXa alone increased the expression level of carnitine palmitoyltransferase I and II, two mitochondrial long chain fatty acid transporters. Rivaroxaban also prevented the increased expression of oxidative stress-related proteins induced by FXa alone. In femoral isolated arteries from type 2 diabetic patients with end-stage vasculopathy, FXa promoted disruption of the aerobic mitochondrial metabolism. Rivaroxaban prevented such effects and even seemed to favour long chain fatty acid transport into mitochondria.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Urea, powder, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
DL-Dithiothreitol solution, BioUltra, for molecular biology, ~1 M in H2O
Sigma-Aldrich
Urea, ACS reagent, 99.0-100.5%
Supelco
DL-Dithiothreitol solution, 1 M in H2O
Sigma-Aldrich
Urea, ReagentPlus®, ≥99.5%, pellets
Supelco
Urea, 8 M (after reconstitution with 16 mL high purity water)
Sigma-Aldrich
Urea solution, BioUltra, ~8 M in H2O
Sigma-Aldrich
Urea, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
Sigma-Aldrich
4,4′-Diaminodiphenylmethane, ≥97.0% (GC)
Sigma-Aldrich
Urea, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99%
Sigma-Aldrich
Urea, BioUltra, for molecular biology, ≥99% (T)
Sigma-Aldrich
Urea, suitable for electrophoresis
Sigma-Aldrich
Urea, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%, 99.0-101.0% (calc. on dry substance)
Supelco
Urea, analytical standard
Sigma-Aldrich
Urea, meets USP testing specifications
Supelco
4,4′-Diaminodiphenylmethane, analytical standard
Millipore
Urea solution, suitable for microbiology, 40% in H2O
USP
Urea, United States Pharmacopeia (USP) Reference Standard
Urea, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Urea-12C, 99.9 atom % 12C
Sigma-Aldrich
Urea solution, 40 % (w/v) in H2O